237 related articles for article (PubMed ID: 29365319)
1. Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications.
Pulte ED; Nie L; Gormley N; Goldberg KB; McKee A; Farrell A; Pazdur R
Blood Adv; 2018 Jan; 2(2):116-119. PubMed ID: 29365319
[TBL] [Abstract][Full Text] [Related]
2. Innovations in treatment and response evaluation in multiple myeloma.
Wester R; Sonneveld P
Haematologica; 2016 May; 101(5):518-20. PubMed ID: 27132277
[No Abstract] [Full Text] [Related]
3. [Not Available].
Hitz F
Praxis (Bern 1994); 2016; 105(21):1255-1260. PubMed ID: 28573955
[No Abstract] [Full Text] [Related]
4. The use of novel agents in multiple myeloma patients with hepatic impairment.
Stansfield LC; Gonsalves WI; Buadi FK
Future Oncol; 2015; 11(3):501-10. PubMed ID: 25675129
[TBL] [Abstract][Full Text] [Related]
5. [Multiple myeloma and other plasma cell dyscrasias].
Nagy Z
Magy Onkol; 2016 Jun; 60(2):154-63. PubMed ID: 27275642
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of primary refractory multiple myeloma and the impact of novel therapies.
Majithia N; Vincent Rajkumar S; Lacy MQ; Buadi FK; Dispenzieri A; Gertz MA; Hayman SR; Dingli D; Kapoor P; Hwa L; Lust JA; Russell SJ; Go RS; Kyle RA; Kumar SK
Am J Hematol; 2015 Nov; 90(11):981-5. PubMed ID: 26214732
[TBL] [Abstract][Full Text] [Related]
7. Recent improvement in survival of patients with multiple myeloma: variation by ethnicity.
Pulte D; Redaniel MT; Brenner H; Jansen L; Jeffreys M
Leuk Lymphoma; 2014 May; 55(5):1083-9. PubMed ID: 23879201
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
Moreau P
Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
[TBL] [Abstract][Full Text] [Related]
9. [Myeloma therapy (3) Trends in development of new drugs].
Ri M; Iida S
Rinsho Ketsueki; 2013 Aug; 54(8):715-8. PubMed ID: 24005429
[No Abstract] [Full Text] [Related]
10. A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.
Kazandjian D; Landgren O
Semin Oncol; 2016 Dec; 43(6):682-689. PubMed ID: 28061986
[TBL] [Abstract][Full Text] [Related]
11. Age and aging in blood disorders: multiple myeloma.
Zweegman S; Palumbo A; Bringhen S; Sonneveld P
Haematologica; 2014 Jul; 99(7):1133-7. PubMed ID: 24986875
[No Abstract] [Full Text] [Related]
12. How is patient care for multiple myeloma advancing?
Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A
Expert Rev Hematol; 2017 Jun; 10(6):551-561. PubMed ID: 28504554
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
[TBL] [Abstract][Full Text] [Related]
14. Sequential or combination therapy for multiple myeloma.
Nooka A; Lonial S
Expert Rev Hematol; 2012 Oct; 5(5):533-45. PubMed ID: 23146057
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ashjian E; Redic K
J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
[TBL] [Abstract][Full Text] [Related]
16. [Molecular targeting agents for multiple myeloma].
Fujii S; Abe M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
[No Abstract] [Full Text] [Related]
17. Elotuzumab as a novel anti-myeloma immunotherapy.
Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
[TBL] [Abstract][Full Text] [Related]
18. Update on proteasome inhibitors in multiple myeloma.
Richardson PG
Clin Adv Hematol Oncol; 2014 Mar; 12(3):179-81. PubMed ID: 24927266
[No Abstract] [Full Text] [Related]
19. [I. Proteasome inhibitor for treatment of multiple myeloma].
Murakami H; Saito T; Handa H
Gan To Kagaku Ryoho; 2013 May; 40(5):583-8. PubMed ID: 23957065
[No Abstract] [Full Text] [Related]
20. Absolute lymphocyte count is unrelated to overall survival in newly diagnosed elderly patients with multiple myeloma treated with immunomodulatory drugs.
Napolitano M; Saccullo G; Bono R; Branca A; Cangialosi C; Mancuso S; Raso S; Quintini G; Lipari MG; Fabbiano F; Specchia G; Dolce A; Di Raimondo F; Siragusa S
Leuk Lymphoma; 2015 May; 56(5):1507-9. PubMed ID: 25139690
[No Abstract] [Full Text] [Related]
[Next] [New Search]
